NCT01496118 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 27 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 27 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG000
- title
- Dose Level 1
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 36 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 36 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG001
- title
- Dose Level 2
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG002
- title
- Dose Level 3
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG003
- title
- Dose Level 4
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg by mouth D 1, 3, 5, 15, 17, 19
- id
- FG004
- title
- Dose Level 5
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG005
- title
- Dose Level 6
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG006
- title
- Expansion Dose Level 4
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG007
- title
- Expansion Dose Level 6
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 2
- group Id
- FG005
- num Subjects
- 2
- group Id
- FG006
- num Subjects
- 14
- group Id
- FG007
- num Subjects
- 10
- type
- Disease progression
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 6
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 10
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 0
- type
- Conditions requiring other treatment not permitted by protocol
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 1
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 3
- type
- Withdrawal by Subject
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 31
- group Id
- FG007
- num Subjects
- 30
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 31
- group Id
- FG007
- num Subjects
- 30
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 27 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 27 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG000
- title
- Dose Level 1
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 36 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 36 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG001
- title
- Dose Level 2
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG002
- title
- Dose Level 3
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG003
- title
- Dose Level 4
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg by mouth D 1, 3, 5, 15, 17, 19
- id
- FG004
- title
- Dose Level 5
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG005
- title
- Dose Level 6
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 45 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 45 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 30 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG006
- title
- Expansion Dose Level 4
- description
- Carfilzomib : cycle 1 - 20 mg/m\^2 IV D1, 2 ; 56 mg/m\^2 IV D 8, 9, 15, 16; cycle 2 to progression - 56 mg/m\^2 IV D 1, 2, 8, 9, 15, 16 Panobinostat : cycle 1 and cycle 2 to progression - 20 mg by mouth D 1, 3, 5, 15, 17, 19 panobinostat: Specified dose on specified days carfilzomib: Specified dose on specified days
- id
- FG007
- title
- Expansion Dose Level 6
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 2
- group Id
- FG005
- num Subjects
- 2
- group Id
- FG006
- num Subjects
- 14
- group Id
- FG007
- num Subjects
- 10
- type
- Disease progression
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 6
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 10
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 0
- type
- Conditions requiring other treatment not permitted by protocol
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 1
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 3
- type
- Withdrawal by Subject
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 31
- group Id
- FG007
- num Subjects
- 30
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 31
- group Id
- FG007
- num Subjects
- 30
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle